



### Purpose

The GSK Immunisation Awards have been developed to reward innovation that improves coverage and timely delivery of childhood, adolescent and adult immunisation.

### Eligibility

To be eligible to apply for a GSK Immunisation Award, the following criteria must be met:

- the person submitting the application must be an employee of, or affiliated with, the organisation whose initiative is being nominated for an Award;
- the person submitting the application must have proper authority to nominate the relevant initiative for an Award, on behalf of their organisation;
- the initiative being nominated for an Award must contribute to the purpose of the Awards and meet one or more of the following Award Criteria:
  - Improve access, coverage and/or timely delivery as per the Australian National Immunisation Program schedule;
  - Improve access, coverage and/or timely delivery for hard-to-reach populations (including geographically distant populations, new Australian immigrants, refugees, asylum seekers);
  - Utilise digital technology and/or social media to improve the Quality Use of Vaccines through innovation;
  - Improve access, coverage and/or timely delivery for indigenous populations;
  - Improve access, coverage and/or timely delivery for international travellers.

### Application Process

#### Phase 1 – Call for Abstracts

Applicants are asked to submit an initial abstract outlining, in no more than 500 words, how the initiative being nominated for an Award meets the relevant GSK Immunisation Award criteria.

#### Phase 2 – Finalist Applications

Finalists selected in Phase 1 will be invited to submit a Finalist Application, including:

- a one-page executive summary;
- an outline of the initiative's activities, achievements to date and how the Award would support the initiative's ongoing activities (maximum 2000 words);
- at least one stakeholder testimonial.

### Awards Selection

The Awards Selection Panel will be comprised of members of the Public Health Association of Australia with sector expertise. Abstracts and Finalist Applications will be reviewed and scored by at least three Selection Panel Members. Selection Panel Members will score the initiative's being nominated for an Award against the following criteria:

- Contribution towards the overall aim of improving coverage and timely delivery of childhood, adolescent and adult immunisation.
- Contribution of the initiative's activities, achievements to date and proposed outcomes to the relevant Award Criteria.
- Contribution to innovation in improving immunisation coverage and delivery.
- Potential to be adapted to other immunisation groups.

Selection Panel Members will be required to declare any conflict of interest in relation to the applications over which they deliberate. In the case of conflict of interest, PHAA will allocate that application to a different panel member. The Selection Panel decisions shall be final and no correspondence will be entered into.

## **Awards Ceremony**

Finalists should use their best endeavours to attend or be represented at the Award Ceremony. Finalists will be invited to attend the 2026 Communicable Diseases & Immunisation Conference Dinner with up to 2 complimentary tickets per finalist application.

## **Award Winner Benefits**

Award winners will receive:

- AUD \$20,000 awards prize, to be used to support the initiative's ongoing activities.
- A GSK Immunisation Award trophy and certificate.
- A travel award of up to AUD \$3,000 to attend the 2027 Communicable Diseases & Immunisation Conference for the purpose of presenting on outcomes arising from the Award.

The awards prize will be divided into three instalments:

1. AUD \$15,000 of the awards funding will be transferred to the awardee within three (3) business days following the award announcement via direct deposit.
2. AUD \$5,000 upon receipt of the award winner's one-year report (due to PHAA by Monday 26 April 2027).
3. PHAA will contact Award winners in February 2027 to arrange registration and travel to attend the Communicable Disease & Immunisation Conference in June 2027.

## **Award Winner Reporting**

Award winners will be required to submit a one-year report on the initiative's activities and outcomes arising from the Award. PHAA will provide Award winners with a Report Template, which will be due no later than Monday 26 April 2027.

## **Confidentiality of Material**

Applications for the Awards will be treated as commercial-in-confidence. Information provided by Applicants will not be released without your prior permission.

## **Privacy**

The Public Health Association of Australia (PHAA) is committed to safeguarding your privacy. Handling of your personal information will be in accordance with [PHAA's Privacy Policy](#). Personal information you provide, including photography at the event, will be used solely for the purpose of PHAA organising and delivering the Awards, and will not be shared with third parties unaffiliated with the Event.

The PHAA's Privacy Policy outlines how we use, store and share personal information, and processes to allow users to access and amend their personal information held by PHAA.

## **Disclaimer**

PHAA will administer the 2026 GSK Immunisation Awards in line with these Terms and Conditions and Awards process outlined on the CDIC26 website (<https://www.cdic2026.com/gskawards>). Applicants enter the Awards at their own risk and PHAA and GSK will not be liable for any loss, damage or expense incurred by the Applicant as a result of entering an application for the Awards.